Insulet Q4 FY25: where the revenue came from and where it went
The whole income statement of Insulet for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 18, 2026
Revenue$0.78B
+31% year over year
Gross profit$0.57B
73% margin
Operating profit$0.15B
19% margin
Net profit$0.10B
13% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.78 | 100% | +31% |
| U.S.Omnipod | 0.57 | 73% | +28% |
| International omnipod | 0.21 | 27% | +51% |
| Drug delivery | <0.01 | 0% | −84% |
| Cost of revenue | −0.22 | 27% | |
| Gross profit | 0.57 | 73% margin | +0pp |
| R&D | −0.09 | 12% | +1pp |
| SG&A | −0.33 | 42% | −1pp |
| Operating profit | 0.15 | 19% margin | +0pp |
| Interest & other costs | −0.01 | ||
| Tax | −0.04 | ||
| Net profit | 0.10 | 13% margin | −4pp |
129 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest